CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
CureVac N.V. (Nasdaq: CVAC) has appointed Dr. Mehdi Shahidi, a clinical oncologist and drug development expert, as an independent director to its Supervisory Board. Dr. Shahidi replaces Ralf Clemens, who served from March 2016 through September 2023. The appointment is effective at the CureVac SE level from September 2024, with consideration for CureVac N.V. at the next Annual General Meeting in June 2025.
Dr. Shahidi brings extensive experience in executive leadership and drug development, particularly in clinical oncology. He is currently the CEO of Petalion Therapeutics and a Venture Partner at Medicxi. His previous role as Senior Vice President, Global Head of Medicine and Chief Medical Officer at Boehringer Ingelheim International saw him oversee five drug approvals and advance over 30 candidates into clinical trials.
CureVac N.V. (Nasdaq: CVAC) ha nominato il Dr. Mehdi Shahidi, oncologo clinico ed esperto in sviluppo farmaceutico, come amministratore indipendente nel Consiglio di Sorveglianza. Il Dr. Shahidi subentra a Ralf Clemens, che ha ricoperto la carica da marzo 2016 a settembre 2023. La nomina sarà effettiva a livello di CureVac SE da settembre 2024, con considerazione per CureVac N.V. alla prossima Assemblea Generale Annuale di giugno 2025.
Il Dr. Shahidi porta con sé un'ampia esperienza nella leadership esecutiva e nello sviluppo di farmaci, in particolare nell'oncologia clinica. Attualmente è CEO di Petalion Therapeutics e Venture Partner presso Medicxi. Nel suo precedente ruolo di Vicepresidente Senior, Responsabile Globale della Medicina e Direttore Medico di Boehringer Ingelheim International, ha supervisionato cinque approvazioni di farmaci e ha portato oltre 30 candidati in fase di sperimentazione clinica.
CureVac N.V. (Nasdaq: CVAC) ha nombrado al Dr. Mehdi Shahidi, oncólogo clínico y experto en desarrollo de medicamentos, como director independiente en su Consejo de Supervisión. El Dr. Shahidi reemplaza a Ralf Clemens, quien ocupó el cargo desde marzo de 2016 hasta septiembre de 2023. La designación será efectiva a nivel de CureVac SE a partir de septiembre de 2024, con consideración para CureVac N.V. en la próxima Junta General Anual en junio de 2025.
El Dr. Shahidi aporta una amplia experiencia en liderazgo ejecutivo y desarrollo de medicamentos, especialmente en oncología clínica. Actualmente es CEO de Petalion Therapeutics y Socio de Riesgo en Medicxi. En su cargo anterior como Vicepresidente Senior, Jefe Global de Medicina y Director Médico de Boehringer Ingelheim International, supervisó cinco aprobaciones de medicamentos y avanzó más de 30 candidatos a ensayos clínicos.
CureVac N.V. (Nasdaq: CVAC)는 임상 종양학자이자 약물 개발 전문가인 Mehdi Shahidi 박사를 독립 이사로 감독 위원회에 임명했습니다. Shahidi 박사는 2016년 3월부터 2023년 9월까지 재직한 Ralf Clemens의 후임이 됩니다. 이 임명은 2024년 9월부터 CureVac SE 차원에서 유효하며, 2025년 6월 다음 연례 주주 총회에서 CureVac N.V.에 대한 적절한 고려와 함께 진행됩니다.
Shahidi 박사는 임원 리더십과 약물 개발, 특히 임상 종양학 분야에서 폭넓은 경험을 가지고 있습니다. 그는 현재 Petalion Therapeutics의 CEO이자 Medicxi의 벤처 파트너로 활동하고 있습니다. 이전에는 Boehringer Ingelheim International의 수석 부사장, 글로벌 의학 책임자 및 최고 의료 책임자로 재직하며 5건의 약물 승인을 감독하고 30건 이상의 후보를 임상 시험으로 발전시켰습니다.
CureVac N.V. (Nasdaq: CVAC) a nommé le Dr. Mehdi Shahidi, oncologue clinicien et expert en développement de médicaments, en tant que directeur indépendant de son Conseil de Surveillance. Le Dr. Shahidi remplace Ralf Clemens, qui a occupé ce poste de mars 2016 à septembre 2023. La nomination prendra effet au niveau de CureVac SE à partir de septembre 2024, avec une considération pour CureVac N.V. lors de la prochaine Assemblée Générale Annuelle en juin 2025.
Le Dr. Shahidi apporte une vaste expérience en leadership exécutif et en développement de médicaments, en particulier en oncologie clinique. Il est actuellement PDG de Petalion Therapeutics et partenaire de capital-risque chez Medicxi. Dans son précédent rôle de vice-président senior, responsable mondial de la médecine et directeur médical chez Boehringer Ingelheim International, il a supervisé cinq approbations de médicaments et fait avancer plus de 30 candidats dans des essais cliniques.
CureVac N.V. (Nasdaq: CVAC) hat Dr. Mehdi Shahidi, einen klinischen Onkologen und Experten für Arzneimittelentwicklung, als unabhängigen Direktor in seinen Aufsichtsrat berufen. Dr. Shahidi tritt die Nachfolge von Ralf Clemens an, der von März 2016 bis September 2023 tätig war. Die Ernennung tritt ab September 2024 auf Ebene von CureVac SE in Kraft, wobei CureVac N.V. bei der nächsten Hauptversammlung im Juni 2025 berücksichtigt wird.
Dr. Shahidi bringt umfangreiche Erfahrungen in der Führung und Arzneimittelentwicklung mit, insbesondere in der klinischen Onkologie. Derzeit ist er CEO von Petalion Therapeutics und Venture Partner bei Medicxi. In seiner vorherigen Position als Senior Vice President, Global Head of Medicine und Chief Medical Officer bei Boehringer Ingelheim International oversee er fünf Arzneimittelzulassungen und förderte mehr als 30 Kandidaten in klinische Studien.
- Appointment of Dr. Mehdi Shahidi, an experienced oncologist and drug development expert, to the Supervisory Board
- Dr. Shahidi's expertise aligns with CureVac's focus on technology innovation and R&D, particularly in mRNA-based cancer vaccines
- Dr. Shahidi's track record includes overseeing five drug approvals and advancing over 30 candidates into clinical trials
- None.
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today named clinical oncologist Mehdi Shahidi, M.D., as an independent director to the company's Supervisory Board. Dr. Shahidi replaces Ralf Clemens, who served on the Supervisory Board from March 2016 through September 2023.
"Dr. Shahidi represents a particularly impactful addition to the CureVac board as we sharpen our focus on technology innovation and R&D, and especially as we move forward in laying the clinical foundations for a new generation of mRNA-based cancer vaccines," said Jean Stéphenne, Chairman of CureVac's Supervisory Board. "With his extensive experience bringing innovative therapeutic candidates into the clinic and moving them onward to approval, Dr. Shahidi will be an invaluable asset to our team."
Dr. Shahidi brings extensive expertise in executive leadership and drug development to the board, in his specialty area of clinical oncology and beyond. He is currently the CEO of Petalion Therapeutics, a UK-based biotechnology company developing targeted dendrimer therapies in oncology as well as a Venture Partner at Medicxi, a leading European life sciences investment firm. He was previously Senior Vice President, Global Head of Medicine and Chief Medical Officer at Boehringer Ingelheim International, where over a course of a 15-year career, he oversaw five drug approvals and the advancement of more than 30 candidates into the clinic.
Dr. Shahidi's appointment takes effect at the CureVac SE level as of beginning of September 2024, with his appointment in regard to CureVac N.V. to be considered at the next Annual General Meeting in June 2025.
"CureVac's long-standing innovation in mRNA puts this company in an ideal position to open up whole new modalities in oncology and beyond," said Dr. Shahidi. "I look forward to working alongside my fellow Supervisory Board members and the executive leadership of CureVac to maximize the potential of this groundbreaking technology for patients."
About CureVac
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.
CureVac Media Contact
Patrick Perez, Junior Manager Public Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1831
M: +49 151 14 115247
patrick.perez@curevac.com
CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com
Forward-Looking Statements CureVac
This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
SOURCE: CureVac
View the original press release on accesswire.com
FAQ
Who is the new independent director appointed to CureVac's (CVAC) Supervisory Board?
When will Dr. Shahidi's appointment to CureVac (CVAC) take effect?
What is Dr. Shahidi's current role outside of CureVac (CVAC)?
How many drug approvals did Dr. Shahidi oversee at Boehringer Ingelheim International?
